The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application for elivaldogene autotemcel (eli-cel) for the treatment of cerebral adrenoleukodystrophy in patients less than 18 years of age without a matched sibling donor.
Cerebral adrenoleukodystrophy (CALD) is a rare, X-linked metabolic disorder caused by mutations in the ABCD1 gene, which affects the production of adrenoleukodystrophy protein (ALDP). Eli-cel is an investigational one-time gene therapy designed to add functional copies of the ABCD1 gene into a patient’s own hematopoietic stem cells, resulting in the production of ALDP.
The application is supported by data from the phase 2/3 Starbeam study (ClinicalTrials.gov Identifier: NCT01896102), which evaluated the efficacy and safety of eli-cel in 32 patients with active CALD. Findings showed that 90.6% (n=29/32) of patients achieved major functional disabilities (MDR)-free survival at 24 months.
The application also includes data for 23 patients being evaluated in the phase 3 ALD-104 study (ClinicalTrials.gov Identifier: NCT03852498), which has now completed enrollment. Patients who completed Starbeam, along with those who complete ALD-104, are eligible to enroll in a long-term follow-up study (ClinicalTrials.gov Identifier: NCT02698579).
In clinical trials, myelodysplastic syndrome, viral cystitis, pancytopenia, and vomiting were observed in patients treated with eli-cel.
A Prescription Drug User Fee Act (PDUFA) target date of June 17, 2022 has been set for the application.
bluebird bio announces FDA Priority Review of Biologics License Application for eli-cel gene therapy for cerebral adrenoleukodystrophy (CALD) in patients without a matched sibling donor. News release. bluebird bio, Inc. December 17, 2021. Accessed December 20, 2021. https://www.businesswire.com/news/home/20211217005659/en/bluebird-bio-Announces-FDA-Priority-Review-of-Biologics-License-Application-for-eli-cel-Gene-Therapy-for-Cerebral-Adrenoleukodystrophy-CALD-in-Patients-Without-a-Matched-Sibling-Donor.
This article originally appeared on MPR